Skip to main content
Premium Trial:

Request an Annual Quote

Silence Therapeutics Cleared to Begin German Phase I Trial of Cancer Rx

Premium

Silence Therapeutics this week announced that German regulators have approved the company's application to begin a phase I study of its siRNA-based cancer drug Atu027.

Atu-027 is a systemically administered drug comprising modified, blunt-ended siRNAs targeting PKN-3, a protein kinase that company researchers have linked to tumor growth and metastases, that have been formulated with a mixture of cationic and fusogenic lipids.

The open-label study will test single and repeated intravenous doses of the drug in patients with advanced solid tumors. It is expected to begin "immediately following successful patient enrollment" and will take about 18 months to complete, according to Silence.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.